(Alliance News) - Integumen PLC said Wednesday the current level of pipeline activity is "significantly higher than the company has experienced in the past".
As a result, the skincare firm said it has doubled its laboratory size.
"Demand continues to increase for the company's products and services. The board is satisfied that it is meeting its objective of increasing the average revenue per client as it evolves into a multiple revenue stream product and services company for skin related diseases, treatments and therapies," the company explained.
Non-Executive Chair Ross Andrews added: "The company has been completely transformed over the last 12 months. The objective of disposing of non-performing subsidiaries and incorporating fully integrated teams of skilled personnel, across multiple subsidiaries, with a single focus of increasing revenue per-existing client and closing bigger deals with new clients has been met."
Andrews continued: "The growth of the company has been so well supported and received by the market that all corporate activity has been achieved, funding in place to accommodate the continued growth, and legacy share disposals from former directors and associated companies have been absorbed by the market, leaving no overhang, as we head into an exciting second half of 2019. The board is grateful for this support and looks forward to providing you with continued updates as we progress."
Shares in Integumen were up 3.2% in afternoon trade in London on Wednesday at 1.88 pence each.
